Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) EBT Margin (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed EBT Margin for 7 consecutive years, with 126.32% as the latest value for Q4 2025.

  • Quarterly EBT Margin rose 439997.0% to 126.32% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 140.22% through Dec 2025, up 9641.0% year-over-year, with the annual reading at 145.89% for FY2025, 9844.0% up from the prior year.
  • EBT Margin hit 126.32% in Q4 2025 for BridgeBio Pharma, up from 154.5% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 9.02% in Q1 2024 to a low of 43350.3% in Q3 2022.
  • Historically, EBT Margin has averaged 7918.53% across 5 years, with a median of 4392.27% in 2023.
  • Biggest YoY gain for EBT Margin was 11131155bps in 2021; the steepest drop was -4088617bps in 2021.
  • Year by year, EBT Margin stood at 1805.66% in 2021, then crashed by -330bps to 7760.96% in 2022, then tumbled by -42bps to 11008.94% in 2023, then surged by 59bps to 4526.28% in 2024, then surged by 97bps to 126.32% in 2025.
  • Business Quant data shows EBT Margin for BBIO at 126.32% in Q4 2025, 154.5% in Q3 2025, and 164.3% in Q2 2025.